Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 0.65 |
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578112 | 0.93 | MCHR1 (0.73) | MCHR1ACHEHTR1ADRD2HTR2A | |
| Trifluoroacetic Acid SCHEMBL6807224 | 0.93 | ACHE (0.57) | MCHR1ACHEHTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL5578270 | 0.92 | MCHR1 (0.72) | MCHR1ACHEHTR1ADRD2HTR2A | |
| Trifluoroacetic Acid SCHEMBL6807521 | 0.92 | MCHR1 (0.56) | MCHR1ACHEHTR1ADRD2HTR2A | |
| Trifluoroacetic Acid SCHEMBL6796340 | 0.91 | ACHE (0.60) | MCHR1ACHEHTR1ADRD2HTR2A | |
| Trifluoroacetic Acid SCHEMBL6807538 | 0.90 | MCHR1 (0.54) | MCHR1ACHEHTR1ADRD2HTR2A | |
| Trifluoroacetic Acid SCHEMBL6803142 | 0.90 | ACHE (0.56) | MCHR1ACHEHTR1ADRD2HTR2A | |
| Trifluoroacetic Acid SCHEMBL6802674 | 0.89 | ACHE (0.56) | MCHR1ACHEHTR1ADRD2HTR2A | |
| Trifluoroacetic Acid SCHEMBL6807576 | 0.86 | MCHR1 (0.50) | MCHR1ACHEHTR1ADRD2HTR2A | |
| Trifluoroacetic Acid SCHEMBL6807608 | 0.85 | MCHR1 (0.62) | MCHR1ACHEHTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | GPR142, GPR139, GPR4 | MCHR1 191/4885ACHE 4719/4885HTR1A 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.